Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
HALOZYME THERAPEUTICS, INC. filed an initial ownership report for Interim CFO David A. Ramsay. This Form 3 shows his status as an officer but does not list any equity transactions or holdings in the provided data. It is an administrative disclosure of insider status rather than a trading event.
Halozyme Therapeutics, Inc. has issued its 2026 proxy for an online-only annual stockholder meeting on May 5, 2026. Stockholders will vote on electing two Class I directors, an advisory say-on-pay resolution for named executive officers, and ratifying Ernst & Young LLP as auditor for 2026.
The Board highlights a majority-vote standard for uncontested director elections, a fully independent board except for the CEO, and active board committees overseeing audit, compensation, and governance. Executive pay is heavily weighted to performance-based equity, with 2025 incentives tied to revenue and Adjusted EBITDA goals and strong stock performance, including record 2025 revenue of $1,397 million and 52% royalty revenue growth.
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while it continues an active search for a permanent CFO. Ramsay previously served as Halozyme’s CFO across multiple periods and has more than 30 years of financial leadership in biotechnology.
As Interim CFO he will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units that vest on June 30, 2026, subject to continued employment and a one-year holding period. If he remains Interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs that vest on his employment termination date, also with a one-year holding period.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported an exercise-and-sell transaction in company stock. On March 9–10, 2026, she exercised options to acquire a total of 21,546 shares of common stock at an exercise price of $33.51 per share.
Over the same two days, she conducted open-market sales totaling 28,857 shares of common stock at weighted average prices around $67.64–$68.25, with specific trades executed in price ranges disclosed in the footnotes. Following these transactions, she directly holds 7,055 shares of common stock and retains 67,678 options to purchase common stock.
HALO submitted a Form 144 notice reporting proposed sales of Common stock and disclosing a recent sale. The filing shows a reported sale by Cortney A. Caudill of 20,000 shares on 03/09/2026 for $1,356,062. The notice lists several issuances/vestings and an option exercise with quantities of 4,663, 1,546, and 2,648 shares tied to vesting or exercise dates in 2024–2026.
Morgan Stanley Smith Barney LLC reports a Rule 144 sale notice for 20,000 common shares. The filing states the shares relate to an exercise of options under a registered plan and lists the transaction date as 03/09/2026 on NASDAQ. The filing indicates cash as the consideration and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a combination of option exercises and share sales. Over March 2–4, 2026, she exercised options to acquire 50,000 shares of common stock at an exercise price of $12.07 per share.
She then sold 50,000 shares of common stock in multiple open‑market transactions under a pre‑established Rule 10b5‑1 trading plan, at weighted average prices within ranges between $68.22 and $71.36 per share. After these transactions, she directly owned 767,780 common shares.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported routine equity award activity. On February 20, 2026, 2,666 Restricted Stock Units vested and were settled into 2,666 shares of common stock, reflecting an exercise or conversion of derivative securities at a stated price of $0.0000 per share.
To cover tax withholding obligations from this vesting, 1,037 common shares were automatically withheld by the issuer at a price of $70.98 per share, as noted in the footnotes. After these transactions, Caudill directly owned 14,366 shares of common stock and 7,998 Restricted Stock Units. These movements reflect compensation-related settlements and tax withholding rather than open-market buying or selling.
Halozyme Therapeutics SVP and Chief Legal Officer Mark Howard Snyder reported multiple equity compensation events. On February 20 and 23, 2026, restricted stock units vested and were settled into 5,332 and 7,011 shares of common stock, respectively, through derivative exercises at $0.00 per share.
To satisfy tax withholding obligations, the issuer withheld 2,876 shares at $70.98 and 3,782 shares at $70.64, recorded as tax-withholding dispositions rather than open-market sales. After these transactions, Snyder directly owned 47,610 shares of Halozyme common stock.